Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: tocilizumab

Marching to the Biosimilar Beat: Questions on Rollout Remain

Ruth Jessen Hickman, MD  |  September 7, 2023

The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

Filed under:Drug UpdatesHome Slider Tagged with:adalimumabBiosimilarsRA Resource Center

Cardiovascular Safety with RA Treatments

Michele B. Kaufman, PharmD, BCGP  |  March 2, 2023

Research by Chicre et al. found that Janus kinase inhibitors may significantly increase the risk of major adverse cardiac events and all-cause death in patients with rheumatoid arthritis (RA) when compared with other RA treatments. This study highlights the need for more comparative safety studies.

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:cardiovascularcardiovascular eventJAK inhibitorJanus Kinase InhibitorsRA Resource CenterRheumatoid Arthritis (RA)TNF inhibitorsTofacitinib

3 AC&R Study Summaries: Treat to Target in Gout, Response to Biologics in Patients with JIA, & Rehabilitation Dose in Adults with RA

Arthritis Care & Research  |  February 14, 2023

Treat to Target in Gout Monitoring & achievement of target serum urate levels By Jing Li & Gabriela Schmajuk, MD, MS Why was this study done? The ACR’s 2020 guideline for the management of gout recommends using a treat-to-target (T2T) approach to lower serum urate (SU). Using the ACR’s RISE registry, we examined the use…

Filed under:ConditionsGout and Crystalline ArthritisPediatric ConditionsResearch RheumRheumatoid Arthritis Tagged with:GoutGout Resource Centerjuvenile idiopathic arthritis (JIA)

Case Report: Adult-Onset Still’s Disease with Complications

Cristina Romaniello, DO, & Caitlin Kesari, MD  |  February 14, 2023

The following report outlines a case of newly diagnosed adult-onset Still’s disease (AOSD) complicated by macrophage activation syndrome (MAS) in a previously healthy and active 32-year-old man who had emigrated from Africa to the U.S. Case A man with no prior medical history presented with acute-onset polyarthritis, fevers and fatigue that began one month previously….

Filed under:ConditionsOther Rheumatic Conditions Tagged with:adult Still's Diseasecase reportmacrophage activation syndrome

Lost and found

A Look Back at the First Use of Cortisone in Rheumatoid Arthritis

Ruth Jessen Hickman, MD  |  January 17, 2023

In 1949, the first description of patients with rheumatoid arthritis (RA) given cortisone sent shockwaves through the medical community, quickly capturing the public imagination as well. The paradigm-shifting report paved the way for the use of cortisone and related drugs in RA and many other medical conditions.1 The following is a discussion of some of…

Filed under:ConditionsRheumatoid Arthritis Tagged with:cortisoneLost & Found

FDA Officials Speak Out: New Approvals & Safety Concerns Discussed

Thomas R. Collins  |  December 13, 2022

PHILADELPHIA—Officials from the U.S. Food & Drug Administration discussed recent drug approvals and drug safety issues at ACR Convergence in November in a session that captured the flurry of activity in the rheumatology sphere at the agency over the past year. Sabiha Khan, MD, clinical reviewer in the Division of Rheumatology and Transplant Medicine at…

Filed under:ACR ConvergenceDrug UpdatesLegislation & AdvocacyMeeting ReportsProfessional Topics Tagged with:ACR Convergence 2022drug approvalsFDA

Mitigating Drug Shortages: FDA Officials Say Communication Is Crucial

Thomas R. Collins  |  December 13, 2022

PHILADELPHIA—The most vital component of avoiding drug shortages is early communication, officials from the U.S. Food & Drug Administration (FDA) said in a session at ACR Convergence 2022 in November. “Early notification is key in order to prevent and mitigate shortages,” said Hyun Son, PharmD, a member of the Drug Shortage Staff with the FDA…

Filed under:ACR ConvergenceDrug UpdatesLegislation & AdvocacyMeeting ReportsProfessional Topics Tagged with:ACR Convergence 2022Drug shortageFDA

Rheumatology Medications with Limited Safety Data: How Do We Use Them in Pregnant Patients?

Samantha C. Shapiro, MD  |  December 6, 2022

How does a rheumatologist treat a pregnant woman when many medications are not approved for pregnancy or safety data are limited?

Filed under:ACR ConvergenceBiologics/DMARDsConditionsDrug UpdatesMeeting ReportsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2022belimumabcyclophosphamideLupus nephritismycophenolate mofetilprednisonepregnancyreproductive carerituximabsystemic lupus erythematosus (SLE)tocilizumabvoclosporin

What You Need to Know About COVID-19 & Therapies for Rheumatic Diseases

Jason Liebowitz, MD, FACR  |  December 6, 2022

PHILADELPHIA—Since March 2020, the world has been turned upside down by the COVID-19 pandemic. Rheumatologists must understand how to best protect and treat their patients with autoimmune conditions at risk for infection due to immunosuppressive therapy. At ACR Convergence 2022, the session titled, Latest COVID and Rheumatic Disease Therapies: What You Need to Know, provided…

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2022COVID-19

Clinical Rheumatology Year in Review—2022

Samantha C. Shapiro, MD  |  December 4, 2022

In this overview of clinical updates in rheumatology in the last year, high-impact studies were discussed, including the GLORIA, ORAL Surveillance and MIRROR trials.

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:ACR Convergence 2022COVID-19pegloticaseprednisolone

  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 29
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences